Published online Aug 8, 2020. doi: 10.4292/wjgpt.v11.i3.59
Peer-review started: December 29, 2019
First decision: March 27, 2020
Revised: May 17, 2020
Accepted: May 21, 2020
Article in press: May 21, 2020
Published online: August 8, 2020
Processing time: 219 Days and 20.8 Hours
Sarcopenia in patients with chronic liver disease has prognostic implications. L3 skeletal muscle index (L3SMI) calculated from computed tomography (CT) images is currently the only objective and reproducible method accepted for the quantification of sarcopenia. This study aims to determine tongue thickness measured using ultrasonography as an alternative method for diagnosing sarcopenia.
Sarcopenia in patients with chronic liver disease has prognostic implications. Wider application of L3SMI calculated from CT images is limited by cost, the need for extensive training, limited availability and due to the risk of radiation exposure. Clinical researchers have suggested the inclusion of a measure of sarcopenia in established prognostic models for patients with liver disease. A dependable and reproducible method with wider availability is therefore needed.
This study aimed to examine tongue thickness measured using ultrasonography as a dependable bedside tool for the diagnosis of sarcopenia. Significant differences were seen in tongue thickness between healthy individuals and individuals with less severe liver disease compared to patients with more severe chronic liver disease.
Patients with chronic liver disease and healthy individuals who satisfied the inclusion criteria underwent tongue thickness measurement using ultrasonography. The study was observational in nature and no intervention was planned on the basis of observations made. Tongue thickness measurements were compared between healthy individuals and patients with liver disease of different severity. The imaging technique used was ultrasonography, which has wider availability and does not involve radiation exposure unlike CT scanning used to measure L3SMI.
Significant differences were seen in tongue thickness between healthy subjects and patients with less severe liver disease compared to patients with more severe liver disease. Tongue thickness measured using ultrasonography is therefore proposed as a bedside measure of sarcopenia. However, its application requires further validation in studies involving subjects of different ethnicity, in health and in disease.
This study established consistent and significantly reduced tongue thickness in patients with severe liver disease compared to healthy individuals and patients with less severe liver disease. Tongue thickness measured using ultrasonography may therefore be used as a bedside tool for the diagnosis of sarcopenia, an application with wide availability and no risk of radiation exposure compared to CT-based measurement of L3SMI.
The findings in this study require validation in a similar study of tongue thickness using ultrasonography in people of different ethnicity in health and in disease.